Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2024-10-08 00:00:00 ET · period of report 2024-10-04 · accession 0001213900-24-086271 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-08 | 2024-10-04 | MLTX | Sturge Simon | Dir | S - Sale | $53.72 | -171.0K | 172.0K | -50% | -$9.19M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2024-10-04 | S | D | 171,000 | $53.72 | 171,980 | D | — | — | (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $53.00 to $55.34. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |